Physician profile
Khoa Vo
NPI 1225094931
$21,313.00
in general payments reported to CMS, 2019-2025
36 companies · $3,254 in 2025
The $3,254 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,096 · 2020: $3,080 · 2021: $3,471 · 2022: $3,082 · 2023: $3,050 · 2024: $3,279 · 2025: $3,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,471 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,471.15 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,642.45 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $1,766.71 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,725.70 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $1,358.90 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,299.16 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $1,141.42 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $1,134.17 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $1,075.94 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $939.20 | 2020-2025 | Caplyta |
| Allergan, INC. | $799.02 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $724.95 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $605.31 | 2019-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $548.11 | 2019-2022 | |
| Neos Therapeutics, Lp | $526.75 | 2019-2025 | Exxua |
| Bausch Health US, LLC | $506.00 | 2019-2025 | Aplenzin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $499.78 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Jazz Pharmaceuticals INC. | $423.18 | 2019-2023 | |
| Alkermes, INC. | $398.46 | 2022-2025 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $384.52 | 2022-2025 | Quviviq, Quviviq |
| Noven Therapeutics, LLC | $349.78 | 2024-2025 | Xelstrym, Secuado, Xelstrym |
| Teva Pharmaceuticals USA, INC. | $349.36 | 2022-2024 | Uzedy, Austedo, Austedo Xr |
| Almatica Pharma LLC | $329.56 | 2021-2025 | Loreev Xr |
| Harmony Biosciences LLC | $279.62 | 2020-2024 | Wakix |
| Adlon Therapeutics L.P. | $261.79 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $255.77 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $245.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $210.33 | 2020-2023 | Belsomra |
| Shire North American Group INC | $149.95 | 2019 | |
| Eisai INC. | $104.70 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $90.71 | 2025 | Lumryz |
| Arbor Pharmaceuticals, INC. | $51.63 | 2019 | |
| Neurocrine Biosciences, INC. | $41.62 | 2023-2025 | Ingrezza |
| Livanova USA, INC. | $34.63 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Neuronetics, INC. | $33.60 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $13.36 | 2019 | |
| Alfasigma USA, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khoa Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.